ArticleGenome medicine2026
Multi-omics profiling of the diabetic human heart reveals coupled dysregulation in lipid metabolism, mitophagy, and extracellular matrix remodeling.
Article in Genome medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Recent advances in mitochondrial fission and fusion in diabetic cardiomyopathy.Frontiers in cardiovascular medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundDiabetic cardiomyopathy (DbCM) is a major complication of type 2 diabetes whose molecular basis in human hearts remains poorly understood. This study aimed to define the multi-omics landscape of DbCM in the human myocardium.
methodsWe performed integrated transcriptomic, 4D-DIA proteomic, and full-spectrum widely targeted metabolomic analysis on left ventricular tissues from matched Chinese cohorts: DbCM (n = 11), non-diabetic cardiomyopathy (n = 11), and healthy donors (n = 4). Key findings were validated by histological assessment and western blotting of candidate proteins. External validation was conducted using public datasets, and phenotypic support was derived from mouse models.
resultsMulti-omics profiling revealed distinct, coordinated dysregulation in DbCM. Proteomics and transcriptomics profiling revealed a rewired fatty acid oxidation-mitophagy axis characterized by elevated acyl-CoA synthetase long-chain family member 1 (ACSL1) and suppressed fatty acid synthase (FASN), impaired mitochondrial quality control marked by a significant reduction in the mitophagy regulator BNIP3L, which showed a strong inverse correlation with ACSL1, and disrupted extracellular matrix homeostasis, with specific downregulation of key structural components (COL5A1, COL5A2, and fibrillin-1). Metabolomics confirmed enhanced but incomplete fatty acid oxidation, evidenced by triglyceride depletion and accumulation of acylcarnitines and lipotoxic lipids. Integrated multi-omics identified impaired BNIP3L-associated mitophagy as a potential molecular node associated with lipid metabolic dysregulation with mitochondrial dysfunction.
conclusionsThis human multi-omics study defines DbCM by the concurrent dysregulation of cardiac fuel metabolism, mitochondrial quality control, and matrix remodeling, offering novel mechanistic insights and highlighting ACSL1 and BNIP3L as potential therapeutic targets for diabetes-associated cardiac dysfunction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.